source
- TME holds onto $1B dream for brain cancer drug as search for partners nears conclusionTME Pharma’s hunt for a partner for its brain cancer drug is closer to bearing fruit as the German biotech clings onto its hope of generating $1 billion in peak sales from the asset.Fierce Biotech · 7h ago↗ source
- Regenxbio gene therapy refiling plan derailed by FDA hold over spine MRI findingsThe FDA has put a clinical hold on Regenxbio’s RGX-121 over asymptomatic spine MRI findings, derailing the biotech’s plans to refile for approval of the once-rejected gene therapy candidate.Fierce Biotech · 9h ago↗ source
- Roche pens $2.5B pact for Hanmi’s clinical-stage obesity drug targeting less-explored mechanismRoche has taken its obesity strategy into uncharted territory via a $190 million upfront payment for a clinical-stage urocortin-2 analog from South Korea’s Hanmi Pharm.